Does definitive local therapy have a role in select HER2+  de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?

ConclusionIn a group of HER2+  dnMBC patients receiving systemic treatment in the era of dual antibody therapy, patients who underwent surgery had a superior 3-year survival rate than those who did not. There may be a role for a prospective trial in HER2+ dnMBC patients with an excellent response to dual HER2 blockade to inv estigate the contribution of curative intent local therapy to the primary tumor compared to systemic therapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research